CAS: 1345982-69-5

Linerixibat

Linerixibat (GSK2330672) is a highly effective, nonabsorbable ASBT inhibitor. Linerixibat can lower glucose in an animal model of type 2 diabetes.

Linerixibat is an investigational pharmaceutical compound classified as an ileal bile acid transporter (IBAT) inhibitor. It is derived from chemical synthesis and acts by selectively targeting the IBAT, also known as the apical sodium-dependent bile acid transporter (ASBT), located in the distal ileum of the small intestine. By inhibiting this transporter, Linerixibat reduces the reabsorption of bile acids from the intestinal lumen, which leads to increased fecal bile acid excretion and reduced systemic levels of bile acids. The primary application of Linerixibat is in the management of cholestatic pruritus, particularly in patients with conditions such as primary biliary cholangitis (PBC). Cholestatic pruritus is a symptom associated with liver disorders characterized by elevated levels of bile acids that can lead to significant discomfort and impaired quality of life. Linerixibat's ability to modulate the enterohepatic circulation of bile acids provides a novel therapeutic approach by addressing the underlying pathophysiology of this pruritus. The compound is currently under investigation in clinical trials to evaluate its efficacy and safety profile.